NCT06327100: Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF) |
|
|
| Not yet recruiting | 2 | 33 | US | Ruxolitinib, Jakafi, INCB018424, INC424, Tasquinimod | M.D. Anderson Cancer Center, Active Biotech AB | Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-Essential Thrombocytosis Myelofibrosis | 05/29 | 05/31 | | |
NCT04405167: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma |
|
|
| Recruiting | 1 | 34 | US | Tasquinimod, IRd chemotherapy, Ixazomib, Lenalidomide, Dexamethasone | University of Pennsylvania, Active Biotech AB | Multiple Myeloma | 07/24 | 07/25 | | |